Amgen Announces Positive Result For Phase 1b Study Of Combination Of Vectibix, Lumakras

Amgen Inc. (AMGN) Monday announced positive results for its phase 1b CodeBreaK 101 trial and confirmed 30 percent objective response rate for its Amgen's Vectibix in a combination with Lumakras/Lumykras in patients with KRAS G12C-Mutated Metastatic colorectal cancer. The trial showed a median progression-free survival of 5.7 months in a difficult-to-treat patient population, while the current standard of care offers a median progression-free survival benefit of two months. Vectibix is a monoclonal anti-epidermal growth factor receptor antibody.

Amgen said Lumakras plus Vectibix achieved a 30 percent confirmed objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer, where treatment response rates can be as low as 2 percent.

The company said it will focus on combination approaches in colorectal cancer, including advancing CodeBreaK 300, the Phase 3 Lumakras plus Vectibix trial in the chemotherapy-refractory patient population.

The trial enrolled 40 patients with heavily pre-treated KRAS G12C-mutated chemo-refractory mCRC. Disease control was seen in 37 patients for a total of 92.5 percent with a median progression-free survival of 5.7 months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT